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ABSTRACT 
This work describes a rapid analytical method based on direct sample injection of water 
samples for the simultaneous identification/quantification of 40 emerging compounds, 
including pharmaceuticals and drugs of abuse. The water samples were analyzed by ultra-
high-performance liquid chromatography coupled to hybrid triple quadrupole mass 
spectrometer (UHPLC-MS/MS QqQ). Taking profit of the increasing sensitivity of 
nowadays’s tandem mass spectrometers, direct sample injection of large volumes has been an 
attractive alternative to pre-concentration steps. In this work, the developed methodology has 
been validated at three concentration levels (10, 100 and 1000 ng/L) in 10 different water 
samples of different types (5 effluent wastewaters and 5 surface waters). The majority of 
compounds could be satisfactory validated at these concentrations, showing good recoveries 
and precision. With only few exceptions, the limits of quantification (LOQs), estimated from 
the sample chromatogram at lowest spiked level tested, were below 3 ng/L. The method was 
applied to the analysis of 10 effluent wastewaters and 10 surface water samples. Venlafaxine 
was the compound most frequently detected (80%) in surface water, followed by 
acetaminophen (70%). Regarding effluent wastewater, valsartan and 4-acetyl aminoantipyrine 
were detected in 9 out of 10 samples analyzed. These two compounds together with 4-formyl 
aminoantipyrine and naproxen showed the highest concentrations (>2000 ng/L). In these 
cases, a dilution step was required for a correct quantification. As an additional evaluation of 
the method performance, the same water samples were analyzed in other laboratory by a 
second analytical methodology, based on on-line solid-phase-extraction coupled to LC-
MS/MS (QqQ). 
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1. INTRODUCTION 
The presence of human and veterinarian pharmaceuticals, as well as illegal drugs of abuse, in 
environmental samples has been recognized as a potential environmental threat [1,2]. These 
groups of contaminants are of present concern, due to their very high biological activity, 
psychoactive properties and still not well known effects to the aquatic environment [1,3]. 
After their consumption, these compounds can be excreted as the parent compound, as 
metabolites or as a mix of unchanged compound plus metabolites, reaching first the 
wastewater treatment plants (WWTPs) and finally the aquatic environment if they are not 
completely removed by WWTPs. The concentrations of these compounds in the environment 
depend on many factors, including their consumption pattern and use, the percentage of 
wastewater collected and the characteristics of the processes used for wastewater treatment 
[4]. Recently, several works have reported the presence of drugs and metabolites in the 
environmental, showing concern for its unknown impact [5–7]. 
Current analytical methods developed for quantifying low concentration of pharmaceuticals 
[2,8–10] and illicit drugs [11,12] in aquatic samples, usually include pre-concentration steps, 
the most common being those based on solid-phase extraction (SPE). Extraction from water 
samples has usually been performed by off-line SPE [5,6,8,9,11], although on-line SPE-LC 
has also been reported as a time and cost-saving alternative thanks to its fully automation 
[7,13]. Large-volume injection (LVI) is an attractive approach for aqueous samples that has 
been applied in several works as a rapid and efficient alternative to conventional SPE [14–
18]. Typically, LVI involves the direct injection of sample volumes that range from 100 to 
5000 µL versus the more conventionally injected volumes of 10-20 µL [14]. The 
improvement in sensitivity comes from the injection of sample volumes larger than usual. 
LVI provides good reproducibility and low sample contamination as a consequence of the 
minimal sample handling. Moreover, it allows to increase sample throughput at minimal cost 
compared to both off- and on-line SPE, because no SPE cartridges and solvents are needed 
[14]. Despite the injection of larger volumes, modern and sensitive instruments are commonly 
needed for final measurement, as the increase in injection volume does not compensate the 
pre-concentration factors normally reached by SPE. In addition, peak shape may be 
deteriorated for early eluting analytes when increasing injection volume despite the lower 
eluotropic strength of water sample. Moreover, only clean water is usually directly injected in 
the system otherwise matrix effects could not be properly compensated for. Although, we 
show that effluent wastewater might be considered clean water in our LVI approach. 
Modern multi-class methods applied for the determination of polar pharmaceuticals or drugs 
of abuse are mostly based on liquid chromatography (LC). The use of UHPLC in combination 
with tandem mass spectrometry (MS/MS) using triple quadrupole (QqQ) [2,8,10,11,19–22] or 
ion trap (IT) analyzers [23–27], has made possible the development of faster and more 
sensitive methods. Moreover, the fact of working with short dwell times in new instruments, 
allows increasing the number of selected reaction monitoring (SRM) transitions acquired 
simultaneously per compound making possible not only quantification but also a reliable 
identification. Although LC-MS/MS is the technique of choice at present to analyze polar 
compounds in aquatic samples, the presence of pharmaceuticals in environmental samples has 
also been investigated by LC coupled to high resolution mass spectrometry (HRMS), using 
time-of-flight (TOF MS) [28–30] or Orbitrap analyzers [31–33]. HRMS analyzers have strong 
potential for large screening and for identification/elucidation purposes, but they show less 
sensitivity than state-of-the-art MS/MS instruments, making that LC-MS/MS are considered 
the optimum analyzers for quantification at trace level. 
The goal of the present paper is to develop fast and sensitive analytical methodology 
combining the advantages of UHPLC-MS/MS with last-generation triple quadrupole and 
large-volume direct sample injection. Thus, a rapid method avoiding sample manipulation 
(i.e. pre-concentration and clean-up) has been developed for the determination of forty highly 
consumed compounds, including pharmaceuticals, drugs of abuse and some veterinary drugs, 
in waters. The quantitative validation has been performed at three concentration levels (10, 
100 and 1000 ng/L) in 5 surface water (SW) and 5 effluent wastewater (EWW) samples. 
Several isotopically-labelled internal standards have been tested for correction of expected 
matrix effects. In order to evaluate the applicability of the method, 20 water samples (10 SW 
and 10 EWW) were analyzed. The same samples were analyzed by another laboratory using a 
methodology based on on-line SPE-LC-MS/MS (QqQ).  
2. EXPERIMENTAL 
2.1. Reagents and chemicals 
Pharmaceutical reference standards were purchased from Sigma–Aldrich (St Louis, MO, 
USA), LGC Promochem (London, UK), Toronto Research Chemicals (Ontario, Canada), 
Across Organics (Geel, Belgium), Bayer Hispania (Barcelona, Spain), Fort Dodge Veterinaria 
(Gerona, Spain), Vetoquinol Industrial (Madrid, Spain) and Aventis Pharma (Madrid, Spain). 
All reference standards presented purity higher than 93%. 
Illicit drugs and metabolites studied were amphetamine, 3,4-
methylenedioxymethamphetamine (MDMA or ecstasy), cocaine, cocaethylene and 
benzoylecgonine. These compounds were obtained from Sigma–Aldrich (Madrid, Spain), 
Cerilliant (Round Rock, TX, USA) and the National Measurement Institute (Pymble, 
Australia) as solutions in methanol, acetonitrile or as salt. 
Standard stock solutions of each compound were prepared at 100 mg/L in methanol or 
acetonitrile. Intermediate solutions (10 mg/L) were prepared by dilution of the stock solution 
ten-fold with methanol. Mixed working solutions containing all analytes were prepared daily 
from intermediate solutions by appropriate dilution with water, and were used for preparation 
of the aqueous calibration standards and for spiking samples in the validation study. 
Isotopically-labelled internal standards (ILIS) of omeprazole-d3, acetaminophen-d4, 
diclofenac-d4, valsartan-d8, carbamazepine 10,11-epoxide-d10 and salicylic acid-d3 were from 
CDN Isotopes (Quebec, Canada); atorvastatin-d5 from Toronto Research Chemicals and 
sulfamethoxazole-13C6 and trimethoprim-
13C3 were from Cambridge Isotope Laboratories 
(Andover, MA, USA). Deuterated drugs of abuse were purchased from Cerilliant as solutions 
in methanol or acetonitrile at a concentration of 100 mg/L (amphetamine-d6, MDMA-d5, 
benzoylecgonine-d3, cocaine-d3 and cocaethylene-d8). A mix ILIS working solution at 100 
µg/L was prepared in MeOH and used as internal standard. All solutions were stored in amber 
glass bottles at −20 °C. 
HPLC-grade methanol (MeOH), HPLC-grade acetonitrile (ACN), formic acid (HCOOH, 
content >98%), ammonium acetate (NH4Ac, reagent grade) and sodium hydroxide (NaOH, 
>99%) were purchased from Scharlab (Barcelona, Spain). HPLC grade water was obtained 
from distilled water passed through a Milli-Q water purification system (Millipore, Bedford, 
MA, USA). 
2.2. Instrumentation 
UHPLC analysis were carried out with a Waters Acquity ultra-performance liquid 
chromatography (UPLC) system (Waters, Milford, MA, USA), equipped with a binary 
solvent manager and a sample manager. Chromatography separation was performed using an 
Acquity UPLC BEH C18 1.7 µm particle size analytical column 100 mm × 2.1 mm (Waters). 
The mobile phases used were A = H2O and B = MeOH, both with 0.01% HCOOH and 1mM 
NH4Ac. The percentage of organic modifier (B) was changed linearly as follows: 0 min, 5%; 
7 min, 90%; 8 min, 90%; 8.1 min, 5%; 10 min, 5%. The flow rate was 0.4 mL/min. The 
column was kept at 40 °C and the sample manager was maintained at 5 °C. Analysis run time 
was 10 min. The sample injection volume was 100 μL. 
A Waters Acquity UPLC system was interfaced to a triple quadrupole mass spectrometer 
Xevo TQS (Waters) equipped with an orthogonal Z-spray electrospray ionization interface 
(ESI) operated in positive and negative ion mode. Cone gas as well as desolvation gas was 
nitrogen (Praxair, Valencia, Spain) set up 250 L/h and 1200 L/h, respectively. For operation 
in the MS/MS mode, collision gas was argon 99.995% (Praxair, Madrid, Spain) with a 
pressure of 4 x 10-3 mbar in the collision cell (0.15 mL/min). Other parameters optimized 
were: capillary voltages 3.5 kV (ESI+) and 3.0 kV (ESI-); source temperature 150 °C and 
desolvation temperature 650 °C. Cone voltage was selected as 10 V for all compounds, due to 
no variations were observed. Dwell times were automatically selected in order to obtain 
enough points per peak and can be decreased down to 3 ms. 
All data were acquired and processed using MassLynx v 4.1 software (Waters). 
2.3. Sample preparation 
All water samples were centrifuged at 4500 rpm for 5 min. 1-mL surface water or effluent 
wastewater was spiked at 50 ng/L with the ILIS mix. 100 µL of the sample were directly 
injected in the UHPLC–MS/MS system. 
2.4. Validation study 
Acquisition was performed in SRM mode, with the (de)protonated molecular ion of each 
compound chosen as precursor ion. The most abundant product ion of each target analyte was 
typically used for quantification and two additional product ions were used for confirmation. 
LC retention time was also compared with that of the reference standards (within ±2.5%) to 
help to confirm the compounds detected in samples. 14 compounds were quantified using 
their corresponding labelled analyte as internal standard and 5 compounds were quantified 
using an analogue IS (see Table 2). The remaining 21 compounds were quantified by external 
calibration using absolute responses. 
The linearity of the method was studied by analyzing standard solutions in triplicate at eight 
concentrations, in the range from 1 to 2500 ng/L. Satisfactory linearity was assumed when the 
correlation coefficient (r) was higher than 0.99, based on relative responses (analyte peak 
area/ILIS peak area), except for those compounds that were quantified without ILIS (absolute 
response). 
Method accuracy (estimated by means of analysis of spiked samples directly injected into the 
LC-MS/MS system) and precision (expressed as repeatability, in terms of relative standard 
deviation (RSD)) were evaluated in surface water and effluent wastewater, spiked at three 
concentrations (10, 100 and 1000 ng/L). A total of 10 different water samples were used for 
the method validation (5 effluent wastewater and 5 surface water samples). Quantification 
was made by using calibration standards in solvent and relative or absolute responses as a 
function of the ILIS was used or not for matrix effects correction. Recovery values between 
70% and 120%, with RSD lower than 20% were considered as satisfactory. The limit of 
quantification (LOQ) was estimated for a signal to noise (S/N) ratio of 10 from the sample 
chromatograms at the lowest validation level tested, using the quantification transition. 
Adequate blank samples were not found for several analytes as they were present in all 
samples collected. In these cases, LOQ values were estimated from the chromatograms of the 
non-spiked “blank” samples, considering the concentration levels. 
2.5. Water samples 
20 water samples (10 EWWs and 10 SWs) were collected in polyethylene high-density bottles 
in selected sites of the Spanish Mediterranean area (Castellon and Valencia provinces). 
Composite EWW samples were collected from different WWTPs using primary and 
secondary treatment methods. Grab SW were sampled from different rivers (3), reservoirs (3) 
and lakes (4). All samples were taken from October to December in 2012. Samples were 
stored at −18 ºC until analysis. Before analysis, samples were thawed at room temperature. 
2.6. On-line SPE LC-MS/MS QqQ 
An alternative analytical methodology was also applied following the protocol used in routine 
analysis by an ISO 17025 certified laboratory in Spain (IPROMA S.L.). For LC analysis, an 
Agilent 1200SL binary pump was coupled to a hybrid triple quadrupole/linear ion trap mass 
spectrometer system API3200QTRAP from Applied Biosystems-Sciex (Foster City, 
California, USA). On-line SPE was performed by using an Agilent 1200 pump and a Strata-X 
cartridge (2 × 20 mm, 25 μm) from Phenomenex (Torrance, CA, USA). This equipment also 
includes a PAL autosampler (CTC Analytics, Switzerland) for automated sample injection. 
The injection volume to the on-line SPE was 2 mL of water, previously centrifuged at 2500 
rpm for 5 min (wastewater samples were diluted 1/20). Chromatographic separation was 
performed on a reversed-phase column ZORBAX Eclipse XDB-C18 (50 × 4.6 mm, 1.8 μm) 
from Agilent (Palo Alto, CA, USA) maintained at 40 °C. Mobile phases A and B were 0.1% 
formic acid in water and 0.1% formic acid in methanol, respectively. The following linear 
gradient was used: hold at 95%A for 4.5 min, decreased to 70%A over 4.6 min, decreased to 
0%A over 6.5 min and then increased to 95%A over 10.1 min, returning to the initial 
conditions. The flow rate was set to 600 μL/min [34].  
3. RESULTS AND DISCUSSION 
In this work, 35 human and veterinary pharmaceuticals and 5 drugs of abuse were selected 
(Table 1). Eight pharmaceuticals were among the most widely consumed in Spain [35]. The 
rest of compounds were selected due to their reported presence in water samples and to their 
potential negative effect on living organisms of the aquatic environment. Moreover, 4 
compounds corresponded to metabolites of pharmaceuticals: salicylic acid, metabolite of 
acetylsalicylic acid [36]; and 4-aminoantipyrine, 4-acetyl aminoantipyrine and 4-formyl 
aminoantipyrine, metabolites of dipyrone [37,38,39]. 
3.1. MS/MS optimization 
Individual standard solutions were directly infused in the MS/MS system. The majority of the 
compounds (33 out of 40) were determined with ESI operating in positive ionization mode, 
using the protonated molecule [M+H]+ as precursor ion. The 7 remaining compounds were 
determined in negative ionization using [M-H]- as precursor ion. The three most sensitive 
SRM transitions (in terms of signal-to-noise ratio) were selected for each compound. The 
most abundant was used for quantification (Q) whereas the other two transitions were 
acquired for confirmation (q1, q2). The only exception was salicylic acid (only one transition), 
and gemfibrozil and naproxen (two transitions) because of their poor fragmentation. MS/MS 
parameters as well as SRM transitions and retention times are listed in Table 1. This table 
also shows the average (q/Q) ratios obtained from the calibration standards. The RSDs for 
q/Q ratios illustrate whether these ratios might be considered to be concentration dependent or 
not (e.g. RSD < 15% would indicate little variation of the q/Q values over the concentration 
range tested, from 1 to 2500 ng/L). 
Three SRM transitions were acquired per compound, whereas for ILIS, only the 
quantification transition was monitored. Using our fast-acquisition triple quadrupole mass 
analyzer, dwell times as low as 3 ms per transition could be automatically set-up allowing 
satisfactory peak shape (at least 10 points-per peak) and sensitivity for all 40 compounds 
investigated. 
3.2. UHPLC conditions 
In this work, different mobile phases (acetonitrile and methanol) with different composition 
(HCOOH and NH4Ac at various concentrations) were tested. The effects of pH and ionic 
strength of the mobile phase on the peak shape, resolution and efficiencies were evaluated by 
varying the buffer concentration. Finally, a gradient consisting of water (solvent A) and 
MeOH (solvent B) both with 1 mM ammonium acetate and 0.01% formic acid was chosen as 
an appropriate mobile phase. 
Initially, 10 µL were injected in the system as reference conditions. In order to further 
improve sensitivity, injection of increasing sample volumes was performed. On the basis of 
the column dimensions and the particle size (in this case, 2.1 x 100 mm, 1.7 µm), the dead 
volume of the column was estimated to be 400 µL. The recommended injection volume 
should not exceed the 10% of this dead volume, this is, 40 µL. Trying to perform LVI for this 
system, 50 and 100 µL were tested, obtaining satisfactory chromatographic peak shape in all 
cases. The best sensitivity was achieved when injecting 100 µL. Hence, the injection of 100 
µL was selected for further validation. 
3.3. Matrix effects: quantification 
The high complexity and variability of the matrices in water samples (especially in 
wastewaters) affected considerably the recovery values of some compounds. For almost half 
of the studied compounds, matrix effects resulting in ionization suppression were observed, 
being more important in EWW samples than in SW. Thus, acetaminophen and atorvastatin 
showed recoveries between 60-120% in the five SW tested, but decreased down to 27-60% in 
EWW. A few compounds experimented ionization enhancement due to co-eluted matrix 
components, leading to recoveries >100%. This was the case of levamisol, MDMA or 
trimethoprim. Among the different approaches proposed in the literature to remove or 
compensate for the matrix effects, the use of isotopically-labeled internal standards (if 
available) was considered the preferred option. Fourteen compounds could be corrected with 
their own ILIS, as they were available to our laboratory, obtaining satisfactory figures after 
correction, as expected. Erythromycin, levamisol, pravastatin, sulfadiazine and venlafaxine 
were corrected using an analogue ILIS (Table 2). The selection of analogue ILIS was mainly 
based on chemical structure and/or retention time similarity between analyte and ILIS, as it 
was expected that both were affected by similar constituents of the matrix. In particular cases, 
e.g. erythromycin, an ILIS eluting at different retention time and with different chemical 
structure (sulfamethoxazole-13C6) was able to perform an efficient matrix effects correction, 
as previously reported by Gracia-Lor et al. [8]. The rest of the analytes were quantified using 
absolute response as matrix effects in the ten water samples tested were not much relevant.  
3.4. Method validation  
Analytical characteristics of the method were evaluated in two types of water samples: five 
surface water and five effluent wastewater samples, spiked at three concentration levels each 
(10, 100 and 1000 ng/L).   
The linearity of the method was studied in the range 1-2500 ng/L for all compounds. 
Calibration curves showed in all cases correlation coefficients greater than 0.99, and residuals 
lower than 25%. 
Accuracy and precision were estimated from injection of different water samples spiked at the 
three concentrations indicated above. All the “blank” samples contained at least one or more 
target analytes. Thus, the samples were previously analyzed and those with lower drug 
concentration were selected as “blank” samples for method validation. Concentration of target 
compounds found in these “blank” samples were subtracted from the spiked samples. 
The results obtained for most compounds were satisfactory at the three validation levels, with 
recoveries between 70-120% and precision (RSD) below 20% (Table 2). At the lowest level 
(10 ng/L) amphetamine, diclofenac, olanzapine, roxithromycin and salicylic acid could not be 
validated, due to their lower sensitivity. For some compounds, validation was not feasible in 
all the samples tested due to the high analyte concentration found in different “blank” samples 
(e.g. the three dipyrone metabolites or gemfibrozil). In these cases, the number of data used in 
validation was less than 10 (5 SW and 5 EWW) (highlighted as * or ** in Table 2).  
The method presented satisfactory precision for most compounds with RSDs below 20% at 
the three fortification levels. Regarding LOQ, they were ≤3ng/L for 32 out of 40 compounds 
in SW. For another 5 analytes LOQs ranged from 3 to 7 ng/L, and for the remaining 3 were 
slightly higher, between 12-38 ng/L. In EWW, 29 compounds presented LOQs ≤3ng/L, 7 
ranged from 3 to 9 ng/L and the remaining 4 were between 12-41 ng/L. According to our 
data, it seems that the type of water did not much affect the attainable sensitivity despite of 
being a direct injection method. 
3.5. Analysis of water samples  
To demonstrate the applicability of the method developed, 10 effluent wastewater and 10 
surface water samples were analyzed. In every sequence of analysis, a calibration curve in 
solvent was injected at the beginning and at the end of the batch sample. Quality controls 
(QCs) were also included in every sequence, consisting on selected EWW and SW samples 
spiked with all pharmaceuticals at 100 ng/L. QC recoveries were satisfactory (in the range of 
70-120%) for the majority of the compounds. However, QCs recoveries for venlafaxine 
(using atorvastatin-d5 as IS) and for levamisol (using cocaethylene-d8) were around 130%. As 
it has been already reported in the literature, the use of analogues IS does not always assure an 
efficient matrix effects correction [40,41]. 
Identification of positive findings was supported by evaluation of q1/Q and q2/Q ratios. The 
finding was considered as positive when retention time and at least one experimental ion-ratio 
were within the established tolerances [42], when compared with a reference standard. 
Although the acquisition of two SRM transitions per compound together with the accordance 
in the retention time are normally considered sufficient for a reliable confirmation of the 
compound identity, in this work three transitions were acquired in order to increase the 
confidence of the confirmation process [40]. Using three transitions, one can minimize the 
possibilities of reporting false negatives when the ion ratio is not accomplished, in those cases 
where one of the transitions seems to be interfered. As an example, Figure 1 shows positive 
findings of alprazolam, bezafibrate and sulfamethoxazole in EWW. As it can be seen, the 
three transitions showed a peak at the same retention time. Moreover, at least one q/Q ratio 
was within tolerance limits. 
Tables 3 and 4 show the concentration values (ng/L) found for each compound in EWW and 
SW, respectively. 32 analytes were detected in the 10 EWWs analyzed, illustrating the 
frequent occurrence of drugs in wastewaters and the fact that many of them are not 
completely removed in WWTPs. Carbamazepine, used for the treatment of epilepsy and 
bipolar disorder, was the compound most frequently detected, appearing in all samples 
analyzed. This was followed by the angiotensin II antagonist valsartan and 4-acetyl 
aminoantipyrine (metabolite of the analgesic dipyrone), which were present in 90% of 
EWWs. 4-formyl aminoantipyrine (another metabolite of dypirone), the anthelmintic 
levamisol, the antibiotics sulfamethoxazole and trimethoprim, and the antidepressant 
venlafaxine appeared in 80% of EWWs. The highest concentrations corresponded to 4-acetyl 
aminoantipyrine (7.2 µg/L), valsartan (4.6 µg/L), 4-formyl aminoantipyrine (3.2 µg/L) and 
the analgesic naproxen (1.9 µg/L). In these cases, samples were diluted and re-analyzed to fit 
the linear range of the method.  
In relation to surface waters, up to 26 compounds were detected in the samples analyzed. All 
these compounds were also found in EWWs, normally at higher concentrations. Venlafaxine 
and acetaminophen were the compounds most frequently detected, being present in 80% and 
70% of the samples, respectively. 4-acetyl, 4-formyl aminoantipyrine, cocaine and its 
metabolite benzoylecgonine, were present in 60% of SWs analyzed. The highest 
concentration corresponded to dipyrone metabolites: 4-formyl (0.72 µg/L) and 4-acetyl 
aminoantipyrine (0.66 µg/L). 
As an illustrative example, Figure 2 shows UHPLC-MS/MS chromatograms for SW 4 (only 
the quantitative transition Q is shown), which was positive for 19 out of the 40 target 
compounds. Concentration data for this sample are shown in Table 4, where it can be seen 
that acetaminophen presented the highest value (480 ng/L). Four drugs of abuse 
(benzoylecgonine, cocaethylene, cocaine and MDMA) were also detected in the range of 7-31 
ng/L. These figures reveal that licit and illicit drugs can actually reach surface waters due to 
the incomplete removal in WWTPs. 
  3.5.1. On-line SPE HPLC-ESI-MS/MS 
The same 20 samples were analyzed by another laboratory that applied an analytical 
methodology based on on-line SPE-LC coupled to triple quadrupole mass spectrometry. With 
this methodology, only 25 human and veterinary pharmaceuticals and drugs of abuse were 
included in the target method. All of them were determined with ESI operating in positive 
ionization mode. For confirmation, two SRM transitions at the same retention time, and the 
accomplishment of the q/Q ratios were required. Regarding quantification parameters, two 
internal standards were used to correct possible deviations: diclofenac-13C6 for 
pharmaceuticals and cocaine-d3 for drugs of abuse. The linearity of the method was studied in 
the range 2-150 ng/L for all compounds. The method presented satisfactory accuracy and 
precision for all compounds, with recoveries values >85% and RSDs below 13%. Regarding 
LOQ, they ranged from 2 to 20 ng/L for SW and from 40-400 ng/L for EWW. The on-line 
SPE-LC method was implemented in this laboratory under requirements of ISO-170025 [34]. 
Data obtained are also shown in Tables 3 and 4 (between brackets). Six compounds (cocaine, 
benzoylecgonine, diclofenac, naproxen, sulfamethoxazole and venlafaxine) were found in 
EWW samples, less than in the direct injection methodology (32 compounds). This was 
surely due to the higher LOQs obtained in the on-line procedure, due to the dilution step 
(1/20) applied to EWW samples prior to on-line SPE. The concentration values ranged from 
0.048 to 3.1 µg/L and were in agreement with the results obtained by the direct injection 
approach. Regarding surface water samples, where no dilution was performed, up to 8 
compounds could be detected (benzoylecgonine, cocaine, acetaminophen, clarithromycin, 
diclofenac, levamisol, naproxen and venlafaxine). Among them, venlafaxine was the 
compound most frequently detected (3 out of 10 SW analyzed), and the highest concentration 
found was for acetaminophen (0.65 µg/L). All concentration values obtained by this 
methodology were also in accordance with the results reported after direct injection analyses. 
Except for the differences due to the distinct sensitivity of the two procedures, the 
concentrations found by both of them for the wide majority of positive samples were rather 
similar, supporting the applicability and reliability of our more-sensitive large-volume direct 
injection approach.  
4. CONCLUSIONS  
Analytical methodology based on UHPLC-MS/MS QqQ has been developed for the 
simultaneous quantification and confirmation of 40 human and veterinary pharmaceuticals 
and drugs of abuse in effluent wastewater and surface samples. The direct injection of water 
samples (100 µL), without any previous sample treatment, has been shown as an attractive 
approach as it avoids time-consuming sample preparation steps and reduces the amounts of 
solvents used. The determination of target compounds was performed in positive/negative 
voltage switching mode in a single chromatographic run of only 10 min. With a few 
exceptions, a highly reliable identification of the compounds was feasible thanks to the 
acquisition of three SRM transitions per compound and the accomplishment of the ion ratio 
and retention time deviations. Satisfactory accuracy and precision were obtained in recovery 
experiments at three concentration levels in two kinds of water matrices, EWW and SW, 
using 10 different samples to this aim. The LOQs were in most cases lower than 3 ng/L. The 
application of this method to 10 effluent wastewater and 10 surface samples, allowed the 
detection of 32 and 26 compounds, respectively. Carbamazepine was the compound most 
frequently detect (100%) in EWW and venlafaxine (80%) in SW samples. This methodology 
has been proven to be an attractive and efficient approach for rapid determination of 
pharmaceuticals and drugs of abuse in environmental waters, achieving low LOQs without 
the need for a preliminary pre-concentration step.   
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FIGURE CAPTIONS 
Figure 1. UHPLC-MS/MS chromatograms detected in EWW samples. 
Figure 2. UHPLC-MS/MS chromatograms (Q transition) for a surface water sample (SW 4, 
see Table 4) where 19 target compounds were found. Positive/negative voltage switching 
mode applied within the same run. 
  
Table 1. MS/MS optimized conditions for selected compounds. 
Compound ESI 
TR 
(min) 
Precursor 
ion (m/z) 
Q 
transition 
C.E. 
(eV) 
q1 
transition 
C.E. 
(eV) 
q1/Q 
(RSD) 
q2 
transition 
C.E. 
(eV) 
q2/Q 
(RSD) 
4-Acetyl aminoantipyrine + 2.85 245.9 246 > 228 10 246 > 83 20 0.71(3) 246 > 104 20 0.38(4) 
4-Aminoantipyrine + 3.15 204.1 204 > 56 15 204 > 159 10 0.29(5) 204 > 83 15 <0.01(5) 
4-Formyl aminoantipyrine + 2.81 232.1 232 > 83 20 232 > 104 20 0.63(4) 232 > 214 10 0.63(7) 
Acetaminophen + 1.99 152.1 152 > 110 15 152 > 65 25 0.20(5) 152 > 93 20 0.26(8) 
Alprazolam + 5.77 308.9 309 > 281 25 309 > 205 25 0.11(4) 309 > 274 25 0.21(5) 
Amphetamine + 2.81 136.2 136 > 91 15 136 > 119 10 0.43(6) 136 > 65 10 0.12(15) 
Atorvastatin + 6.68 558.9 559 > 440 20 559 > 466 15 0.20(5) 559 > 292 25 0.17(4) 
Benzoylecgonine + 3.32 290.0 290 > 168 15 290 > 105 25 0.34(6) 290 > 92 25 <0.01(16) 
Bezafibrate - 6.10 359.8 360 > 274 20 360 > 154 25 0.24(5) 360 > 85 15 0.07(6) 
Carbamazepine + 5.32 236.9 237 > 194 20 237 > 192 20 0.24(5) 237 > 179 25 0.08(5) 
Clarithromycin + 6.11 590.0 590 > 158 20 590 > 116 25 0.20(13) 590 > 98 25 0.06(9) 
Cocaethylene + 4.24 318.0 318 > 196 20 318 > 82 25 0.71(4) 318 > 150 25 0.18(7) 
Cocaine + 3.74 304.1 304 > 182 15 304 > 82 25 0.56(8) 304 > 105 25 0.19(9) 
Diclofenac - 6.87 294.1 294 > 250 10 294 > 214 20 0.04(3) 294 > 178 20 <0.01(5) 
Enalapril + 4.99 376.9 377 > 234 15 377 > 117 25 0.24(4) 377 > 303 15 0.30(10) 
Erythromycin + 5.62 734.2 734 > 158 25 734 > 576 15 0.11(5) 734 > 558 15 0.03(10) 
Florfenicol - 3.32 355.7 356 > 336 10 356 > 185 20 1.00(1) 356 > 119 25 0.04(15) 
Flumequine + 5.11 261.9 262 > 244 15 262 > 202 25 0.30(9) 262 > 174 25 0.01(13) 
Furaltadone + 2.37 324.9 325 > 100 20 325 > 252 15 1.00(6) 325 > 281 10 0.77(4) 
Gemfibrozil - 7.46 248.9 249 > 121 20 249 > 127 10 0.07(10)    
Irbesartan + 6.26 428.8 429 > 207 25 429 > 195 20 0.17(2) 429 > 180 25 0.04(4) 
Levamisol + 2.48 205.0 205 > 178 20 205 > 91 25 0.29(10) 205 > 123 25 0.43(11) 
Lincomycin + 2.89 407.0 407 > 126 20 407 > 359 15 0.07(9) 407 > 389 15 0.03(9) 
Lorazepam + 5.76 320.9 321 > 275 20 321 > 303 15 0.50(6) 321 > 229 25 0.34(8) 
MDMA + 2.90 194.0 194 > 163 10 194 > 105 20 0.34(5) 194 > 135 20 0.33(9) 
Nalidixic acid + 4.92 233.0 233 > 215 10 233 > 187 25 0.71(4) 233 > 159 25 0.19(8) 
Naproxen - 6.11 230.2 185 > 169 20 229 > 169 15 0.01(15)    
Olanzapine + 3.25 312.9 313 > 256 20 313 > 84 20 0.56(12) 313 > 213 25 0.45(10) 
Omeprazole + 5.23 345.7 346 > 198 10 346 > 136 25 0.45(3) 346 > 151 15 0.32(4) 
Oxolinic acid + 4.24 261.9 262 > 244 15 262 > 216 25 0.13(12) 262 > 158 25 0.04(8) 
Pantoprazole + 5.18 383.9 384 > 200 10 384 > 138 25 1.10(4) 384 > 153 15 0.36(5) 
Pravastatin - 5.76 423.0 423 > 321 15 423 > 303 15 1.00(5) 423 > 101 25 0.53(11) 
Roxithromycin + 6.22 679.1 679 > 158 25 679 > 116 25 0.22(6) 679 > 98 25 0.04(16) 
Salicylic acid - 4.26 137.0 137 > 93 15       
Sulfadiazine + 2.11 251.0 251 > 156 15 251 > 92 25 0.71(5) 251 > 108 20 0.43(2) 
Sulfadoxine + 3.44 310.9 311 > 156 15 311 > 92 25 0.42(8) 311 > 108 25 0.48(13) 
Sulfamethorxazole + 3.26 253.8 254 > 92 25 254 > 156 15 1.27(7) 254 > 108 20 0.56(6) 
Trimethoprim + 2.88 291.0 291 > 123 25 291 > 230 20 1.11(7) 291 > 261 25 0.83(5) 
Valsartan + 6.27 435.8 436 > 207 25 436 > 235 15 1.12(6) 436 > 261 15 <0.01(17) 
Venlafaxine + 4.61 278.1 278 > 58 15 278 > 260 10 0.43(5) 278 > 121 25 0.24(2) 
ILIS            
Acetaminophen-d4 + 1.89 155.9 156 > 114 15       
Amphetamine-d6 + 2.79 141.7 142 > 93 15       
Atorvastatin-d5 + 6.67 563.9 564 > 445 20       
Benzoylecgonine-d3 + 3.32 293.1 293 > 171 20       
Carbamazepine 10,11-
epoxide-d10 
+ 4.47 263.0 263 > 190 25       
Cocaethylene-d8 + 4.23 326.0 326 > 204 20       
Cocaine-d3 + 3.74 306.9 307 > 185 20       
Diclofenac-d4 - 6.85 299.9 300 > 256 10       
MDMA-d5 + 2.90 199.0 199 > 1650 10       
Omeprazole-d3 + 5.22 348.8 349 > 198 10       
Salicylic acid-d4 - 4.26 140.7 141 > 97 15       
Sulfamethoxazole-13C6 + 3.27 260.0 260 >162 15       
Trimethoprim-13C3 + 2.87 294.1 294 >264 18       
Valsartan-d8 + 6.24 443.9 444 > 207 15       
ES. electrospray ionization; TR, retention time; Q quantification; q confirmation, C.E. collision energy 
 
 
 
 
Table 2. Results of the method validation for effluent wastewater (EWW) and surface water (SW). Limit of quantification (LOQ), recovery (%) and relative standard 
deviation at the three validation levels studied. 
Compound 
SW (n=5)   EWW (n=5) 
ILIS used for correction Recovery (RSD) (both in %) LOQ 
(ng L-1) 
 
Recovery (RSD) (both in %) LOQ 
(ng L-1) 10 ng L-1 100 ng L-1 1000 ng L-1   10 ng L-1 100 ng L-1 1000 ng L-1 
4-Acetyl 
aminoantipyrine 
59 (16)a 79 (19)a 72 (5)a 0.8 
 
95b 69b 78 (14)a 2.0 - 
4-Aminoantipyrine 95 (12)a 74 (14)a 81 (9) 0.7 
 
110b 66b 97b 0.4 - 
4-Formyl 
aminoantipyrine 
72 (13)a 105 (12)a  88 (4)a 1.9 
 
120b 68b 82 (18)a 1.7 - 
Acetaminophen 103 (17)a 111 (10) 107 (9) 1.1 
 
131 (3)a 113 (15) 118 (7) 1.5 Acetaminophen-d4 
Alprazolam 88 (18)a 79 (10) 78 (8) 0.3 
 
81 (16)a 74 (9) 77 (11) 1.2 - 
Amphetamine - 96 (12) 78 (19) 6.3 
 
- 110 (11) 107 (11) 12.5 Amphetamine-d6 
Atorvastatin 84 (11) 85 (7) 100 (9) 0.8 
 
92 (14) 92 (5) 109 (2) 0.8 Atorvastatin-d5 
Benzoylecgonine 88 (18) 83 (7) 97 (10) 0.1 
 
88 (20)a 80 (16) 109 (2) 0.1 Benzoylecgonine-d3 
Bezafibrate 87 (20)a 83 (16) 95 (12) 1.3 
 
82 (11)a 102 (24)a 111 (13) 2.1 - 
Carbamazepine 81 (19) 65 (7) 91 (8) 0.2 
 
77 (16)a 75 (15) 94 (8) 1.1 Carbamazepine 10,11-epoxide-d10 
Clarithromycin 93 (4)a 97 (14)a 90 (9) 2.9 
 
117b 73 (17)a 81 (16) 4.1 - 
Cocaethylene 89 (12) 93 (9) 97 (9) 0.7 
 
100 (5) 93 (5) 102 (4) 0.8 Cocaethylene-d8 
Cocaine 77 (19)a 69 (11) 111 (10) 1.0 
 
70 (9) 88 (17) 116 (3) 1.1 Cocaine-d3 
Diclofenac - 82 (14)a 105 (5) 6.8 
 
- 78 (17)a 104 (11) 7.2 Diclofenac-d4 
Enalapril 99 (17) 88 (6) 92 (5) 0.7 
 
109 (9) 81 (4) 94 (8) 1.8 - 
Erythromycin 115 (6) 85 (15) 72 (14) 0.8 
 
125b 92 (23)a 94 (19) 2.1 Sulfamethoxazole-13C6 
Florfenicol 69 (17) 91 (12) 83 (15) 2.2 
 
97 (11) 84 (14) 109 (11) 8.6 - 
Flumequine 87 (14) 87 (10) 113 (5) 0.4 
 
90 (17) 73 (14) 97 (9) 1.2 - 
Furaltadone 88 (11) 87 (10) 88 (10) 0.7 
 
88 (16) 69 (16) 80 (17) 1.4 - 
Gemfibrozil 83 (15)a 99 (12)a 92 (8) 2.3 
 
103b 92b 90 (18) 1.8 - 
Irbesartan 86 (16)a 87 (13)a 97 (8) 0.2 
 
115b 78 (12)a 99 (5) 1.0 - 
Levamisol 83 (15) 95 (7) 101 (5) 0.2 
 
87 (19)a 98 (16) 106 (10) 2.1 Cocaethylene-d8 
Lincomycin 84 (15)a 81 (17)a 104 (10) 0.1 
 
88 (12) 78 (15) 75 (12) 0.4 - 
Lorazepam 88 (14)a 82 (15) 86 (7) 3.1 
 
109 (9)a 78 (20)a 94 (5) 4.5 - 
MDMA 100 (10) 96 (6) 105 (8) 0.5 
 
99 (18) 93 (2) 103 (8) 1.4 MDMA-d5 
Nalidixic acid 93 (14) 91 (9) 114 (6) 1.8 
 
90 (17) 75 (13) 98 (9) 2.7 - 
Naproxen 77 (18)a 70 (7) 80 (13) 11.7 
 
62b 78b 85 (13) 7.3 - 
Olanzapine - 86 (1)a 108 (12)a 0.8 
 
- - 156 (13) 11.6 - 
Omeprazole 103 (13) 89 (8) 98 (8) 0.2 
 
118 (24) 95 (4) 102 (2) 1.1 Omeprazole-d3 
Oxolinic acid 96 (12) 83 (10) 86 (5) 1.8 
 
98 (13) 70 (10) 80 (16) 2.9 - 
Pantoprazole 93 (15) 99 (8) 103 (5) 0.1 
 
93 (13) 81 (12) 105 (8)  0.8 - 
Pravastatin 96 (14) 81 (13) 85 (13) 15.4 
 
113b 82 (10) 83 (8) 16.7 Diclofenac-d4 
Roxithromycin - 92 (4)a 83 (13) 5.6 
 
- 95 (9)a 91 (16) 5.4 - 
Salicylic acid - - 93 (15) 37.6 
 
- 119b 84 (8) 41.1 Salicylic acid-d4 
Sulfadiazine 102 (16) 99 (9) 116 (8) 1.4 
 
106 (19) 97 (7) 111 (12) 1.8 Sulfamethoxazole-13C6 
Sulfadoxine 85 (12) 83 (11) 104 (7) 0.2 
 
80 (18) 64 (12) 86 (16) 0.5 - 
Sulfamethorxazole 96 (16)a 80 (10) 98 (11) 0.5 
 
103b 83 (10)  106 (7) 0.8 Sulfamethoxazole-13C6 
Trimethoprim 83 (14) 87 (13) 93 (10) 1.8 
 
111b 81 (19) 104 (10) 2.3 Trimethoprim-13C3 
Valsartan 74 (11) 88 (4) 98 (12) 3.8 
 
114b 98 (18)a 89 (14)a 4.2 Valsartan-d8 
Venlafaxine 79 (21)a 78 (15) 102 (11) 0.2   111b 88 (19)a 100 (6) 1.0 Atorvastatin-d5 
 
a Validation performed for n=2-4, due to the high analyte concentration found in some “blank” samples 
b Recovery values without RSD mean (n=1) 
 
 
 
 
 
 
 
 
Table 3. Summary of the results obtained for target pharmaceuticals in EWW, applying the analytical 
methodology described in this article. Between brackets, the concentrations obtained using the on-line SPE-
LC-MS/MS alternative method. 
Compound 
EWW (ng/L) 
1 2 3 4 5 6 7 8 9 10 
4-Aminoantipyrine* 9 15 <LOQ - <LOQ 40 43 14 - 26 
Acetaminophen* - - - 14 - 45 <LOQ - 8 - 
Amphetamine* - 21 - - 29 - - - - - 
Benzoylecgonine* <LOQ 40 (48) 6 <LOQ 656 (735) 11 100 (127) 43 (54) <LOQ 43 (50) 
Clarithromycin* - 14 26 - 34 <LOQ 27 15 - - 
Cocaethylene* - <LOQ - - 15 <LOQ 8 - - <LOQ 
Cocaine* 9 <LOQ - <LOQ 72 (54) 12 - 12 8 24 
Diclofenac* - 266 (251) 884 (1115) - 216 (313) 158 (241) 845 (1181) 300 (386) - 212 (322) 
Erythromycin* 13 55 - - 37 18 49 14 - 25 
Flumequine* - - <LOQ - - - - - - 7 
MDMA* - 45 - - 45 <LOQ - 22 - 48 
Nalidixic acid* - - 17 - <LOQ - - - - 8 
Naproxen* - 42 32 - 1942 (3007) - 515 (642) <LOQ - 357 (419) 
Oxolinic acid* - - - - - - - - - 5 
Pantoprazole* - 5 2 - <LOQ 4 4 7 - 4 
Sulfadiazine* - - 28 - - - - 10 - - 
Sulfamethoxazole* 89 35 372 (308) <LOQ 19 21 29 25 - 29 
Trimethoprim* 15 83 9 - 75 4 13 86 - 25 
Venlafaxine* 
414 
(366) 
316 (282) 421 (389) - 343 (457) 263 (314) 252 (265) 201 (208) <LOQ 239 (260) 
4-Acetyl aminoantipyrine 77 3032 253 - 7239 197 1357 2298 18 689 
4-Formyl aminoantipyrine 860 1583 3425 - 3208 766 1898 1235 <LOQ 853 
Alprazolam 14 11 17 - <LOQ 12 13 10 - 12 
Atorvastatin - 7 - - 16 - - - - <LOQ 
Bezafibrate - 29 - - 87 10 35 16 - 53 
Carbamazepine 112 52 119 3 135 64 149 54 2 90 
Gemfibrozil - 765 4 - 538 25 507 365 <LOQ 95 
Irbesartan - 531 <LOQ - 506 404 799 266 <LOQ 484 
Levamisol 44 311 155 - 150 163 768 178 - 497 
Lincomycin - - - - <LOQ - 6 109 - 7 
Lorazepam - 52 - - 109 58 81 46 - 74 
Pravastatin - 16 - - - - <LOQ <LOQ - - 
Valsartan 41 2864 54 - 4575 291 1457 246 13 399 
*Compounds also analyzed by the on-line SPE LC-MS/MS methodology described in section 
-: not detected 
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Table 4 Summary of the results obtained for target pharmaceuticals in SW, applying the analytical 
methodology described in this article. Between brackets, the concentrations obtained using the on-line SPE-
LC-MS/MS alternative method. 
Compound 
SW (ng/L) 
1 2 3 4 5 6 7 8 9 10 
Acetaminophen* - - - 480 (654) 9 13 13 12 32 (10) 10 
Benzoylecgonine* <LOQ <LOQ 18 (8) 31 (23) 6 <LOQ <LOQ 7 6 6 
Clarithromycin* - - 11 34 (45) - - - - - - 
Cocaethylene* - - - 7 - - - - - - 
Cocaine* 8 <LOQ 8 14 (8) - 8 8 10 (5) - <LOQ 
Diclofenac* - 34 (24) 135 (99) 14 - - - - - - 
Erythromycin* - - 10 <LOQ - - - - - - 
Flumequine* 3 - - - - - - <LOQ - - 
Levamisol* - 4 76 (44) 5 - - - - - - 
MDMA* - - 15 13 - - - - - - 
Nalidixic acid* 3 - - <LOQ - - - 4 - - 
Naproxen* - - 67 (56) 114 (172) - - - - - - 
Oxolinic acid* 5 - - - - - - - - <LOQ 
Pantoprazole* - 1 - - - - - - - - 
Sulfamethoxazole* - 21 25 11 13 <LOQ - - - <LOQ 
Trimethoprim* 3 - <LOQ 5 - - - - - - 
Venlafaxine* 9 244 (217) 93 (61) 30 (18) 16 10 <LOQ <LOQ 9 16 
4-Acetyl aminoantipyrine - <LOQ 719 182 8 9 6 <LOQ - 21 
4-Formyl aminoantipyrine - 9 663 101 33 13 - <LOQ - 60 
Alprazolam - 11 8 <LOQ - - - - - - 
Carbamazepine <LOQ 73 22 10 7 - 2 2 - 6 
Gemfibrozil - - 105 80 - - - - - - 
Irbesartan - <LOQ 5 40 - - - - - 6 
Lincomycin - 12 5 1 - - - - - - 
Lorazepam - 13 18 <LOQ - - - - - 44 
Valsartan - - 13 224 - - - - - - 
*Compounds also analyzed by the on-line SPE LC-MS/MS methodology described in section  
-: not detected 
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